Actively Recruiting
Evaluating Semaglutide Injections for Treating Moderate to Severe Alcohol Use Disorder in Veterans A Randomized, Double-Blind, Placebo-Controlled Trial
Led by VA Office of Research and Development · Updated on 2026-09-21
622
Participants Needed
19
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of semaglutide, a GLP-1 receptor agonist, for treating moderate to severe alcohol use disorder AUD in Veterans. This phase 3 randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of semaglutide compared to placebo. The study addresses the urgent need for new treatments for AUD, especially given the limited success of existing medications and low treatment rates among Veterans. Participants will receive weekly subcutaneous injections of either semaglutide or a placebo for 24 weeks. Semaglutide dosing starts at 0.25 mg for the first four weeks and is gradually increased up to 2.4 mg weekly, based on tolerance. Dose adjustments may slow or reduce to ensure comfort and adherence. Following treatment, there is a 4-week safety assessment period. The trial includes a total of 622 Veterans randomly assigned to either group. During the study, participants will undergo regular assessments including interviews to track daily alcohol consumption using a calendar-based method Timeline Follow-Back. Researchers will evaluate reductions in risky drinking and monitor adverse events. Additional assessments cover quality of life, psychiatric symptoms, alcohol cravings, and healthcare use. The study lasts approximately 32 months for recruitment and intervention, with follow-up and data analysis continuing until 2030.
CONDITIONS
Brief Title
Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)
Research Team
D
David W Oslin, MD
N
Neil C Johnson, MA BA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here